Prevalence of dementia estimated at 10 percent in 2016
Oct 24, 2022
The risk for dementia reduced with each additional year of education; dementia prevalence was higher for Blacks.
Disengaged women especially at risk of cognitive decline in retirement: study
By
Lois A. Bowers
Mar 18, 2020
Results of a new study provide additional motivation for senior living communities to try to keep residents engaged, even in these times of restricted visits and social distancing.
Dietary flavonoids may lower odds of subjective cognitive decline
Jul 30, 2021
Associations were strongest for flavones, flavanones, anthocyanins; the dose-response curve was steepest for flavones, then anthocyanins.
‘Brain training’ program proves ineffective for some applications
By
Alyssa Salela
Jul 17, 2017
A proprietary “brain training” program had no effect on decision-making or cognitive functioning except for basic practice effects in a recent study, according to researchers at the University...
Prevalence of subjective cognitive decline 9.6 percent in ages 45 and up
Mar 13, 2023
Only 47.3% of those with subjective cognitive decline reported that they had discussed issue with healthcare professional.
Incident MI tied to faster declines in cognitive function over time
Jun 05, 2023
Incident myocardial infarction is not associated with a decrease in global cognition, memory or executive function but is associated with faster declines in those measures over time.
MIND diet scores well in ranking
By
Lois A. Bowers
Jan 11, 2016
“U.S. News & World Report” has ranked the MIND diet, said to lower the risk of Alzheimer’s disease, as the easiest diet to follow and the second best overall diet (tying in both categories)...
Sex and the brain
By
Lois A. Bowers
Jun 26, 2017
Results of a new study might create a sense of urgency in both senior living residents and operators regarding sexual expression policies.
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.